Your browser does not support JavaScript!



[2019/10/26] Yang-Ming GLORIA Enterprise Lecture 7: the Establishment of an Exclusive Platform for Biotech Unicorns

Chief Executive Officer Today Su, Golden Biotechnology Corporation, started a series of lively and penetrating speeches on the theme of biotech unicorns. 


Chief Executive Officer Today Su of Golden Biotechnology Corporation, a biotechnology company that has shown outstanding achievement in small molecule drug research and development, was invited to give the Bio-Navigator Lecture in July. With his unique rich experiences and opinions, Chief Executive Officer Su revealed some concepts for promoting biotech industry development that were different from those proposed in the past and were related to the emergence of the next biotech unicorn. His unique and sensational perspectives created innovative inspiration among the audience. 


Chief Executive Officer Su once conducted a clinical experiment in Europe for more than four years. By accident he discovered that European working patterns are very different from those of Asians. Europeans often work as a consultant in a one-person company, whereas Asians tend to work for just one company throughout their lifetime. However, this has become much harder, and will become even harder, to retain a job for life in this ever-changing era, which is now one that is accompanied by the emergence of artificial intelligence (AI). He reckons that you will begin to have a more purposeful and valuable life if there is in place a more systemic approach available to solve the above problems. This should allow you to contribute your expertise and have flexible hours when doing the job that you love. This idea has led to the concept of the Linking Pros Platform. This platform links professionals in the industry together to provide more complete and more professional consulting services. 


In order to establish such a biotech consulting platform, claimed Chief Executive Officer Su, we need to invite biotech talents to join the platform and then select integrated clinical research data to be analyzed by the platform. Only in this way would we be able to accumulate abundant and complete clinical outcomes and provide suitable products for the biotech industry. The successful establishment of this systemic platform would rapidly help us to select suitable research and development products and allow the buildup of an industrial network. This will then result in the creation of biotech unicorns with the highest potential. 


Several professors and students inquired about the platform with enthusiasm. For instance, Director Yang of the NYMU Center for Systems and Synthetic Biology was very interested in how the platform selects talents and how they would assist the biotech industry in creating development strategies. Chairperson Cheng of the Institute of Biochemistry and Molecular Biology inquired about the differences between this platform and the platforms that other countries currently use. Chief Executive Officer Su replied that the platform primarily aims to provide solutions to the industry for investors and funders. They are at present focusing on talents from the talent pool who are experts in clinical trials. The size of the talent pool will expand through recommendation, and this is done to optimize the quality of the talent pool. At present, the scope of this platform is far smaller than similar platforms used overseas. So, for now, we need to cooperate with these overseas platforms in order to train ourselves in platform development and build our own platform interpersonal network. 


A full house at the lecture, which took the audience by storm 


Chief Executive Officer Su emphasized that the biotech industry differs from other industries in that it is built upon research/clinical data, and it is from the accuracy and authenticity of this data that we weave a dream together, giving the industry back its expected value. In the end, he listed and shared with the audience several books that have inspired him. The most representative book among them is “The Black Swan,” which mentions that “people tend to overestimate their knowledge, and underestimate the effect of unknown events.” To overcome this misconception, we should always remind ourselves that there is a difference between self-recognition and practical capability. Before getting involved in the biotech industry, we should, therefore, get to know the products being researched and developed, and then link this with knowledge other than about the products themselves; this will help us to clearly grasp the whole broad expanse of trends in the biotech industry. 



  Vice-President Hsieh recognized Chief Executive Officer Su’s idea regarding the successful system, and presented him with a certificate of appreciation after the lecture.